Arnuity Ellipta

by GlaxoSmithKline (GSK)

Arnuity Ellipta is a once-daily inhaled corticosteroid for asthma available through the GSK Patient Assistance Program.

What is Arnuity Ellipta?

Arnuity Ellipta (fluticasone furoate) is a once-daily inhaled corticosteroid (ICS) approved as a maintenance treatment for asthma in adults and children 5 years and older. As a standalone ICS, it reduces airway inflammation to prevent asthma symptoms and attacks without the added bronchodilator component found in combination inhalers like Breo or Trelegy. It delivers a consistent dose via a simple Ellipta dry powder inhaler device.

Patient Assistance Program

Eligible patients may receive Arnuity Ellipta at no cost through the GSK Patient Assistance Program. ClariMeds handles all application paperwork on your behalf.

Eligibility

  • U.S. resident with a valid prescription
  • Uninsured or underinsured
  • Meets household income requirements

Patient assistance programs

GSK Patient Assistance Program

Manufacturer PAP
Eligibility
Uninsured or underinsured U.S. residents with asthma and a valid Arnuity Ellipta prescription who meet income requirements.
Income limit
Varies based on household size; generally ≤400% of Federal Poverty Level (FPL)
Insurance
Uninsured or underinsured
How to apply
Apply through ClariMeds — we handle all paperwork at no cost to you. Applications are submitted directly to GSK on your behalf.

Need help applying?

ClariMeds handles the entire application process for you — for free. See if you qualify in minutes.

See If You Qualify — Free